Epitalon is part of the July 2026 FDA peptide discussion queue.
Evidence level: Primary regulatory
Sources: U.S. Food and Drug Administration
Use the regulatory record as the anchor for the initial page.
Research peptide
Epitalon
Epitalon is often discussed in longevity-oriented peptide content. The page starts as a regulatory watch entry and should be expanded only after source review.
Regulatory watch
Last reviewed 2026-07-03
Next review 2026-07-24
Evidence snapshot
Treat longevity claims as high-review claims that need precise sourcing and conservative wording.
Scheduled for FDA advisory committee discussion in July 2026.
Longevity-related content is especially prone to claim inflation.
Needs a post-meeting update before expansion.
Tracked claims
Studies from a single Russian research group report that Epitalon increases telomerase activity in human cells.
Evidence level: Peer reviewed
Sources: PubMed / NCBI
The telomerase claim rests on work from the Khavinson group and lacks independent Western replication. Do not present this as established anti-aging evidence.
Online longevity content promotes Epitalon as an anti-aging peptide despite the absence of large-scale human clinical trials.
Evidence level: Community discussion
Sources: PubMed / NCBI, U.S. Food and Drug Administration
Reviews note that geroprotective claims rest on preclinical data from limited research groups. The FDA bulk risk list applies to compounded peptide products.
Free report
Get the source-quality checklist
Use the same checklist Peptide Report uses to separate Epitalon claims, source records, supplier documentation, and media signals.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
Sources on this page
Source records are stored in the repo and linked from each claim.
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
Certain bulk drug substances for use in compounding may present significant safety risks
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.
Peptide regulation of telomerase activity — Khavinson et al. studies of Epitalon
Studies by Khavinson and colleagues reporting that Epitalon (Ala-Glu-Asp-Gly) increases telomerase activity in human somatic cells. Research is primarily from a single Russian research group and lacks independent Western replication.
Epitalon and geroprotective peptides — review of anti-aging claims
Reviews of Epitalon and related peptides in the context of aging biology, noting that telomerase and longevity claims rest on preclinical data from limited research groups without large-scale human clinical trials.
Related compounds
BPC-157
BPC-157 is widely discussed online in injury recovery and performance communities, but the public evidence and regulator...
Regulatory watchDSIP
DSIP appears in online sleep and recovery discussions. This page tracks the topic as a source-backed index entry pending...
Regulatory watchKPV
KPV is a peptide topic appearing in online wellness and research discussions. This page tracks the public source record ...
Regulatory watchSemax
Semax is often discussed online in cognitive and performance contexts. The index treats it as a source-backed watch item...
Regulatory watchStay informed